Ep190: Neil Kumar on Building a Rare Disease Drug Company
The Long Run with Luke Timmerman
00:00
Part B success and clinical outcomes
Neil summarizes the positive 30-month readout showing 42% reduction in combined hospitalization and death.
Play episode from 55:54
Transcript
